复方利福平片对结核分枝杆菌的抗菌作用

目的:研究复方利福平片剂对结核分枝杆菌的体内、体外抗菌活性,并与抗结核药利福平进行比较.方法:采用琼脂稀释法体外检测最小抑菌浓度(MIC);建立结核分枝杆菌的动物感染模型,观察药物在体内的保护作用.结果:体外实验复方利福平对26株结核分枝杆菌有抑制作用,复方利福平片剂中所含利福平的MIC低于单纯利福平的;体内保护实验结果表明,阴性对照组感染小鼠半数存活时间(50% survival time,ST50)为17 d,复方利福平片剂(337.5 mg*kg-1)组其ST50则达29 d.复方利福平片剂的病变指数分别为0.4、0.34、0.24;复方利福平片剂组与空白对照组相比肺重量指数差异有显著性(P<0.01).结论:复方利福平具有较好的抗菌活性.

Antibacterial effect of compound rifampicin tablets on M.tuberculosis

Objective: To examine antibacterial effect of compound rifampicin tablets on isolates of M. tuberculosis in vitro and vivo, and compare it with rifampin. Methods: Use drug diluted Lowenstein Jensen agar medium to determine MIC in vitro and establish infected animal model of tuberculosis to examine protective effect of compound rifampicin tablets in vivo. Results: MIC of compound rifampicin tablets on 26 isolates of M.tuberculosis, especially concentration of rifampicn in compound rifampicin tablets was lower than that of rifampin in control.Results of animal protective test of compound rifampicn from infection with M.tuberculosis shown that ST 50 of compound rifampicin tablets was 29 d ,no significantly difference in comparison with rifampin, whereas ST 50 of control was 17 d ( P <0.01).Lesion index in tested group was ranged from 0 4 to 0 34 and to 0 24 finally, similar to that of rifampin, indicating extremely effectiveness , and weight index of lung was as similar as in rifampin, but less than that of control significantly. Conclusion: Results of experiments of compound rifampicin tablets in vivo and vitro shown effectively antituberculosis equivalent at least to that of rifampin.